Jessica J. O’Konek
Immunology and Microbiology · University of Michigan
Publications
78
Citations
1,070
Est. group size
~10
Recurring co-author estimate
Active years
26
Publishing since 2001
Typically publishes in teams of ~9 · 13% small-team papers (≤3 authors) · across 4 venues
- Animal Models in the Study of Food Allergens: Long-Term Maintenance of Allergic Reactivity in Mouse Models of Food Allergy
Methods in molecular biology · 2023
- CCR Translation for the Article from Synergistic Enhancement of CD8<sup>+</sup> T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody
2023
- Supplementary Figure 2 from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
2023
- Supplementary Figure 1 from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
2023
- Supplementary Figure 3 from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
2023
- Supplementary Figure 1 from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
2023
- Supplementary Figure 3 from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
2023
- Supplementary Figure 2 from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
2023
- Data from Synergistic Enhancement of CD8<sup>+</sup> T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody
2023
- Data from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
2023
- Data from Synergistic Enhancement of CD8<sup>+</sup> T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody
2023
- Data from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
2023
- CCR Translation for the Article from Synergistic Enhancement of CD8<sup>+</sup> T Cell–Mediated Tumor Vaccine Efficacy by an Anti–Transforming Growth Factor-β Monoclonal Antibody
2023
- Editorial: Food allergy: advances in basic and translational animal models
Frontiers in Allergy · 2023
- Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin
OncoImmunology · 2018
- Journal of Allergy and Clinical Immunology×7
- Frontiers in Immunology×4
- Frontiers in Allergy×3
- The Journal of Immunology×3
- Allergy×2
- James J. Moon
Immunology and Microbiology · University of Michigan
- Soo Ngoi
Immunology and Microbiology · The Ohio State University
- Bing Ni
Immunology and Microbiology · University of Michigan
- Diana M. Lopez
Immunology and Microbiology · The Ohio State University
- Fang Ke
Immunology and Microbiology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile